A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin

He, Shengli; Shen, Jie; Sun, Xianjun; Liu, Luming; Dong, Jingcheng

doi:10.1179/1973947813y.0000000133

Cited by 35 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FU therapy, gemcitabine based therapy, sunitinib, and imatinib are among those studied in the second-line setting (11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Median time to progression (TTP) seen with these regimens ranged from 1.6 to 5.5 months.…”

Section: Discussionmentioning

confidence: 99%

Second-line systemic treatment for advanced cholangiocarcinoma.

Rogers

Law

Nguyen

et al. 2014

JCO

View full text Add to dashboard Cite

Background: Gemcitabine plus platinum (GEM-P) combination chemotherapy is standard treatment for first-line advanced cholangiocarcinoma (aCC). GEM-P first-line therapy reports a progression-free survival (PFS) of 8 months and overall survival (OS) of 11.7 months. Treatment in the second-line setting is less clear.Five-year survival for aCC remains dismal at 5-10%. The purpose of this study was to describe the outcomes with second-line systemic treatment at our institution. Results: Fifty-six patients were included and the majority had intrahepatic aCC. A total of 80% received first-line gemcitabine-based therapy. Second-line therapy consisted of GEM-P (19.6%), GEM-FU (28.6%), FU-combo (37.5%), and others (14.3%). Median PFS was 2.7-month (95% CI, 2.3-3.8 months) with a median OS of 13.8 months (95% CI, 12-19.3 months) and a disease control rate of 50%. No significant difference in survival was identified between the four treatment groups.Conclusions: This study revealed a 2.7-month PFS, 50% disease control rate, and potential survival benefit with second-line treatment. Options for second-line systemic therapy include GEM-FU, FU-combo, GEM-P if not given in the first-line setting. Targeted therapy with erlotinib or bevacizumab could be considered in addition to chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Second-line systemic treatment for advanced cholangiocarcinoma.

Rogers

Law

Nguyen

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

“…Despite this, the vast majority of patients develop treatment resistance after few months on therapy and the overall survival (OS) remains at less than 1 year (7). Outcomes in second-line therapies after gemcitabine platinum-based therapy failure result in dismal outcomes with progression-free survival (PFS) only several months, highlighting the need to develop new and effective therapies in BTC ( Table 1) (8)(9)(10)(11)(12)(13)(14).…”

Section: Chemotherapeutic Treatment Optionsmentioning

confidence: 99%

Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications

Ahn

Bekaii‐Saab

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Biliary cancers (BCs) are a diverse group of tumors that arise from the bile duct epithelium and are divided into cholangiocarcinomas of the intrahepatic and extrahepatic cholangiocarcinoma (EHCC) and cancer of the gallbladder. Despite improvements in treatment and diagnosis, BCs are often diagnosed at an advanced stage and associated with poor prognosis and limited treatment options. Recent discoveries have allowed us to have a better understanding of the genomic diversity in BC, and identify genes that are likely contributing to its pathogenesis, proliferation and treatment resistance. Additionally, these advances have allowed us to reason that each anatomic group within BC behave as distinct diseases, with differences in prognosis and outcomes. Based on this knowledge, recent advances have allowed us to identify actionable mutations that form rational therapeutic targets with novel agents, where their relevance will be better understood through the completion of prospective clinical trials.

show abstract

“…docetaxel/erlotinib [81], 5FU/doxorubicin/mitomycin C [82], irinotecan [83], FOLFOX4 [84], sunitinib [72], everolimus [85], bortezomib [86], imatinib [87]. ORR of 0-22.7%, a PFS of 1.6-5.5 months and an OS of 4.1-13.5 months were reported.…”

Section: Accepted Manuscriptmentioning

confidence: 96%